Advancing Science
Patients with melanoma develop brain metastasis at a higher rate than those with any other common cancer. A new study led by NYU Langone Health researchers implicates amyloid beta (Aβ), a polypeptide heavily implicated in neurodegenerative conditions such as Alzheimer's disease, for playing a role in promoting that metastasis. "This study reveals an unexpected role for tumor-secreted amyloid beta in promoting the survival of melanoma brain metastases, and also suggests a new way to counter it," says Eva M. Hernando-Monge, PhD, who led the research team. In a second study, Dr. Hernando-Monge's team identified a protein upregulated in metastatic melanoma cells compared to primary cancer cells that could help to explain why some melanomas metastasize even after being fully resected.
Read More
Recent Articles

Case exemplifies the complex decisions faced by patients with high-risk NMIBC who elect bladder preservation.

Chief Quality Officer Ilseung Cho, MD, discusses the deeper meaning and impact behind NYU Langone’s top accolades for care quality and safety.

NYU Langone Health: A Leader in Cancer
Top 20 cancer hospital in the U.S.
An NCI Comprehensive Cancer Center
200+ active interventional therapeutic clinical trials
Subscribe for Updates from Perlmutter Cancer Center
Follow us on Twitter href="" target="_blank" rel="noopener">@Perlmutter_CC and sign up for Physician Focus emails for practice-changing news and perspectives from our experts at Perlmutter Cancer Center.
Copyright © 2022 NYU Langone Health, All rights reserved.
NYU Langone Health
One Park Avenue, 5th Floor
New York, NY 10016